rhTPO治疗AML患者化疗后血小板减少的疗效分析

Analysis of curative effect by rh TPO in the treatment of post-chemotherapy thrombocytopenia in AML patients

目的：研究重组人促血小板生成素（rhTPO）治疗急性髓系白血病（AML）患者化疗后血小板减少的疗效及不良反应发生情况。方法51例AML化疗后出现血小板减少的患者，随机分为实验组（26例，给予rhTPO治疗）与对照组[25例，给予重组人白细胞介素-11（rhIL-11）治疗]。比较两组患者化疗后血小板恢复的水平、血小板〈50＆#215;109/L的持续天数、恢复至75＆#215;109/L所需天数和恢复至100＆#215;109/L所需天数，以及两组的不良反应发生率。结果治疗后，实验组血小板水平显著高于对照组（P〈0.05），血小板〈50＆#215;109/L的持续天数及恢复至75＆#215;109/L、100＆#215;109/L所需的天数明显少于对照组（P〈0.05）；实验组不良反应发生率低于对照组（7.7% VS 40.0%）（P〈0.05）。结论rhTPO能有效促进AML患者化疗后的血小板恢复，且不良反应发生率低。

ObjectiveTo research curative effect and adverse reactions by recombinant human thrombopoietin （rhTPO） in the treatment of post-chemotherapy thrombocytopenia in acute myelogenous leukemia （AML） patients.MethodsA total of 51 AML patients with post-chemotherapy thrombocytopenia were randomly divided into experimental group （26 cases, rhTPO treatment） and control group [25 cases, recombinant human interleukin-11 （rhIL-11） treatment]. Comparisons were made on post-chemotherapy blood platelet recovery degree, duration time 〈50±109/L, recovery days to 75±109/L, 100±109/L, and incidence of adverse reactions. ResultsAfter treatment, the experimental group had much higher blood platelet level than the control group （P〈0.05）, and its duration time 〈50±109/L, recovery days to 75±109/L, 100±109/L were less than the control group （P〈0.05）. The experimental group had lower incidence of adverse reactions than the control group （7.7% VS 40.0%） （P〈0.05）.ConclusionrhTPO can effectively accelerate post-chemotherapy blood platelet recovery in AML patients, along with low incidence of adverse reactions.